beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes.

Type 2 diabetes is characterized by impaired beta-cell function, hyperglycemia, and islet amyloid deposition. The primary constituent of islet amyloid is the 37-amino acid beta-cell product called islet amyloid polypeptide (IAPP) or amylin. To study mechanisms of islet amyloid formation, we developed a transgenic mouse model that produces and secretes the amyloidogenic human IAPP (hIAPP) molecule and have shown that 81% of male transgenic mice develop islet amyloid after 14 months on a high-fat diet. To test whether impaired beta-cell function and hyperglycemia could enhance islet amyloid formation, we cross-bred our hIAPP transgenic mice with beta-cell glucokinase-knockout mice (GKKO) that have impaired glucose-mediated insulin secretion and fasting hyperglycemia. The resulting new (hIAPPxGKKO) line of mice had higher basal plasma glucose concentrations than the hIAPP transgenic mice at 3, 6, and 12 months of age (P < 0.05), as did GKKO mice compared with hIAPP transgenic mice at 6 and 12 months of age (P < 0.05). Basal plasma immunoreactive insulin (IRI) levels were lower in hIAPP x GKKO mice than in hIAPP transgenic mice at 6 months of age (P < 0.05). The area under the glucose curve in response to an intraperitoneal glucose challenge (1 g/kg body weight) was larger in hIAPPxGKKO mice than in hIAPP transgenic mice at 3, 6, and 12 months of age (P < 0.005) and in GKKO mice compared with hIAPP transgenic mice at 6 and 12 months of age (P < 0.005). The area under the IRI curve was lower in hIAPPxGKKO mice at 6 and 12 months of age (P < 0.05) than in hIAPP transgenic mice and in GKKO mice compared with hIAPP transgenic mice at 12 months of age (P < 0.05). Despite the presence of hyperglycemia, hIAPPxGKKO mice had a lower incidence (4 of 17 vs. 12 of 19, P < 0.05) and amount (0.40 +/- 0.24 vs. 1.2 +/- 0.3 arbitrary units, P < 0.05) of islet amyloid than hIAPP transgenic mice had. As expected, no islet amyloid was observed in GKKO mice lacking the hIAPP transgene (0 of 13). There was no difference in pancreatic content of IRI and hIAPP among the three groups of mice. Thus, despite the presence of impaired islet function and hyperglycemia, hIAPPxGKKO mice had a decreased incidence and quantity of islet amyloid. Therefore, our data suggest that impaired beta-cell glucose metabolism or hyperglycemia are not likely to contribute to islet amyloid formation in diabetes. Furthermore, this finding may explain the lack of progression of glycemia in patients with maturity-onset diabetes of the young.

[1]  Yun-ping Zhou,et al.  Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. , 1994, The Journal of clinical investigation.

[2]  D. A. Trainor,et al.  Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. , 1996, Clinical chemistry.

[3]  E. D. de Koning,et al.  Pancreatic pathology in non-insulin dependent diabetes (NIDDM). , 1995, Diabetes research and clinical practice.

[4]  S. Kahn,et al.  Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.

[5]  J. Thijssen,et al.  Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model , 1999, Diabetologia.

[6]  Michael W. Schwartz,et al.  Evidence of Cosecretion of Islet Amyloid Polypeptide and Insulin by β-Cells , 1990, Diabetes.

[7]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R. Robertson,et al.  Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations. , 1992, The Journal of clinical investigation.

[9]  D. Porte.  β-cells in type II diabetes mellitus , 1991, Diabetes.

[10]  A. Lazarow,et al.  Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats , 1963, Diabetes.

[11]  F M Matschinsky,et al.  A Lesson in Metabolic Regulation Inspired by the Glucokinase Glucose Sensor Paradigm , 1996, Diabetes.

[12]  T. Kodama,et al.  Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor substrate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease. , 1997, The Journal of clinical investigation.

[13]  B. Ahrén,et al.  B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. , 1997, Biochemical and biophysical research communications.

[14]  R. Palmiter,et al.  Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Kahn,et al.  Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. , 1999, Diabetes.

[16]  W. Drohan,et al.  Transgene detection in mouse tail digests. , 1994, BioTechniques.

[17]  F. Sundler,et al.  Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. , 1996, The American journal of physiology.

[18]  N. Eberhardt,et al.  A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. , 1998, The Biochemical journal.

[19]  C. Wernstedt,et al.  A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. , 1986, Biochemical and biophysical research communications.

[20]  R. Turner,et al.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Feinglos,et al.  Defective Glucose‐Stimulated Insulin Release from Perifused Islets of C57BL/6J Mice , 1995, Pancreas.

[22]  K. Polonsky,et al.  Adaptation to hyperglycemia enhances insulin secretion in glucokinase mutant mice. , 1998, Diabetes.

[23]  Y. Yazaki,et al.  Analysis of the Pancreatic β Cell in the Mouse with Targeted Disruption of the Pancreatic β Cell-Specific Glucokinase Gene , 1996 .

[24]  M. Carty,et al.  Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. , 1998, Diabetes.

[25]  D. Steiner,et al.  Effects of beta cell granule components on human islet amyloid polypeptide fibril formation , 1996, FEBS letters.

[26]  S. Kahn,et al.  Consequences of human IAPP expression in transgenic mice , 1996 .